top of page

Deepti Singh, PhD, Founder and CSO of InGel Therapeutics

InGel Therapeutics is pioneering novel stem cell based therapy to bring back light to patients suffering from diverse blinding diseases such as Dry-AMD and Retinitis Pigmentosa. Spun-out from Harvard Medical School, the startup has developed pure stem cell and biomaterial technology to revolutionize the field of regenerative medicine in the eye. The company utilizes stem cells and their secretome for neuroprotection for blinding diseases like retinitis pigmentosa and macular degeneration through biodegradable polymers to isolate proteins of neuroprotective significance first in vitro and later in vivo, enabling healthcare professionals to treat the retinal degeneration of patients.

Lab-to-Launch Lounge

Thursday, Sept. 14, 2023

Deepti Singh is Founder and CSO of InGel Therapeutics, has extensive experience in the study of cellular mechanisms underlying retinal degenerative diseases that she brings to the biotech space. With a Ph.D. in Biogenetics and post-doctoral training from Yale school of Medicine and Harvard Medical school Dr. Singh has a strong background in stem cell biology, Dr. Singh has contributed significantly to the understanding of the cellular pathways involved in retinal diseases. Throughout her career, Dr. Singh has published over 74 papers in top-tier scientific journals, including Nature Communications, Science Advances, and Cell Reports. Her work has focused on elucidating the molecular mechanisms underlying cellular dysfunction in retinal diseases, including age-related macular degeneration (AMD) and retinitis pigmentosa. Dr. Singh's expertise in cellular biology has also led to the filing of 7 international patents related to the development of novel therapies for retinal diseases. She leverages her extensive experience in cell biology to develop a novel therapy for RP and AMD along with other retinal diseases. Her work focus on identifying metabolic dysfunctions and potential therapeutic targets using patient-derived iPSC-RPE cells and in vivo models of retinal degeneration.

One piece of advice to Venturing@Harvard

"Stay open to feedback and be willing to grow, but don't let criticism discourage you. Communicate honestly and openly with others but stand firm in your vision. Be prepared to work hard and face challenges as you pursue your dream, but never lose sight of your underlying purpose and passion."


bottom of page